A Randomized Single-blind Placebo-controlled Study to Evaluate the Safety and Immunogenicity of Three Candidate HIV-1 Vaccines, pSG2.HIVconsv DNA, ChAdV63.HIVconsv and MVA.HIVconsv, Administered in Combination to Healthy HIV 1 Uninfected Adults (HIV-CORE 002)

NCT01151319 Phase 1 COMPLETED

This is a randomised, placebo-controlled, single-blind study designed to evaluate the safety and immunogenicity of three novel HIV vaccines.

Details

Lead sponsor	University of Oxford
Phase	Phase 1
Status	COMPLETED
Enrolment	32
Start date	2010-10
Completion	2014-04

Conditions

• HIV-1 Infections

Interventions

• ChAdV63.HIVconsv low dose.
• ChAdV63.HIVconsv high dose.
• pSG2.HIVconsv
• MVA.HIVconsv
• Placebo

Primary outcomes

• Safety — Actively collected data throughout the study until 6 months after the last vaccination
  Proportion of volunteers who develop a grade 3 or 4 local reaction.

Countries

United Kingdom